Targeting cannabinoid receptor CB2 in cardiovascular disorders: Promises and controversies

British Journal of Pharmacology

Volumn 167, Issue 2, 2012, Pages 313-323

  Steffens, Sabine ^a   Pacher, Pál ^b  

^a University Hospital Foundation for Medical Researches   (Switzerland)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

atherosclerosis; endothelial cells; macrophages; myocardial infarction and reperfusion injury; neointima; restenosis; smooth muscle cells; stroke

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [4 (1,1 DIMETHYLHEPTYL) 2,6 DIMETHOXYPHENYL] 6,6 DIMETHYLBICYCLO[3.1.1]HEPT 2 EN 2 YLMETHANOL; ARACHIDONOYLSERINE; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; DEXANABINOL; DRONABINOL; HU 910; LOW DENSITY LIPOPROTEIN; O 1966; PACLITAXEL; RAPAMYCIN; UNCLASSIFIED DRUG;

APOPTOSIS; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CELL INTERACTION; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; HEART FAILURE; HEART INFARCTION; HEART INFARCTION PREVENTION; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE REMODELING; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; LEUKOCYTE; MACROPHAGE; MONOCYTE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN FUNCTION; REPERFUSION INJURY; RESTENOSIS; REVIEW; SMOOTH MUSCLE FIBER; TRAUMATIC BRAIN INJURY;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; GENE EXPRESSION REGULATION; HUMANS; RECEPTOR, CANNABINOID, CB2;

EID: 84865418404     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02042.x     Document Type: Review

References (97)

1. Aikawa M, Sugiyama S, Hill CC, Voglic SJ, Rabkin E, Fukumoto Y, et al,. (2002). Lipid lowering reduces oxidative stress and endothelial cell activation in rabbit atheroma. Circulation 106: 1390-1396. (Pubitemid 35013044)
2. Ashton JC, Rahman RM, Nair SM, Sutherland BA, Glass M, Appleton I, (2007). Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain. Neuroscience Lett 412: 114-117. (Pubitemid 46074356)
3. Atwood BK, Wager-Miller J, Haskins C, Straiker A, Mackie K, (2012). Functional selectivity in CB2 cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB2 ligands. Mol Pharmacol 81: 250-263.
4. Barutta F, Piscitelli F, Pinach S, Bruno G, Gambino R, Rastaldi MP, et al,. (2011). Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes 60: 2386-2396.
5. Batkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, Mukhopadhyay P, et al,. (2007). Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J 21: 1788-1800. (Pubitemid 46855625)
6. Bittl JA, (1996). Advances in coronary angioplasty. N Engl J Med 335: 1290-1302. (Pubitemid 26349272)
7. Bockaert J, Roussignol G, Becamel C, Gavarini S, Joubert L, Dumuis A, et al,. (2004). GPCR-interacting proteins (GIPs): nature and functions. Biochem Soc Trans 32: 851-855. (Pubitemid 39524396)
8. Bosier B, Muccioli GG, Hermans E, Lambert DM, (2010). Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities. Biochem Pharmacol 80: 1-12.
9. Bouaboula M, Dussossoy D, Casellas P, (1999). Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses. J Biol Chem 274: 20397-20405.
10. Bouchard JF, Lepicier P, Lamontagne D, (2003). Contribution of endocannabinoids in the endothelial protection afforded by ischemic preconditioning in the isolated rat heart. Life Sci 72: 1859-1870. (Pubitemid 36174022)
11. Boudina S, Abel ED, (2007). Diabetic cardiomyopathy revisited. Circulation 115: 3213-3223. (Pubitemid 47012236)
12. Breivogel CS, Childers SR, Deadwyler SA, Hampson RE, Vogt LJ, Sim-Selley LJ, (1999). Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. J Neurochem 73: 2447-2459.
13. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, et al,. (2000). Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396: 141-149. (Pubitemid 30265571)
14. Carrier EJ, Kearn CS, Barkmeier AJ, Breese NM, Yang W, Nithipatikom K, et al,. (2004). Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol 65: 999-1007. (Pubitemid 38420506)
15. Cohen-Yeshurun A, Trembovler V, Alexandrovich A, Ryberg E, Greasley PJ, Mechoulam R, et al,. (2011). N-arachidonoyl-L-serine is neuroprotective after traumatic brain injury by reducing apoptosis. J Cereb Blood Flow Metab 31: 1768-1777.
16. Defer N, Wan J, Souktani R, Escoubet B, Perier M, Caramelle P, et al,. (2009). The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J 23: 2120-2130.
17. Delsing DJ, Leijten FP, Arts K, van Eenennaam H, Garritsen A, Gijbels MJ, et al,. (2011). Cannabinoid receptor 2 deficiency in haematopoietic cells aggravates early atherosclerosis in LDL receptor deficient mice. Open Cardiovasc Med J 5: 15-21.
18. Demuth DG, Molleman A, (2006). Cannabinoid signalling. Life Sci 78: 549-563. (Pubitemid 41785760)
19. Derocq JM, Jbilo O, Bouaboula M, Segui M, Clere C, Casellas P, (2000). Genomic and functional changes induced by the activation of the peripheral cannabinoid receptor CB2 in the promyelocytic cells HL-60. Possible involvement of the CB2 receptor in cell differentiation. J Biol Chem 275: 15621-15628. (Pubitemid 30366856)
20. Di Filippo C, Rossi F, Rossi S, D'Amico M, (2004). Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. J Leukoc Biol 75: 453-459. (Pubitemid 38316376)
21. Doran AC, Meller N, McNamara CA, (2008). Role of smooth muscle cells in the initiation and early progression of atherosclerosis. Arterioscler Thromb Vasc Biol 28: 812-819. (Pubitemid 351544093)
22. Douglas JS, Jr, (2007). Pharmacologic approaches to restenosis prevention. Am J Cardiol 100: 10K-16K.
23. Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, Blond O, et al,. (1995). Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48: 443-450.
24. Ferns GA, Avades TY, (2000). The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol 81: 63-88. (Pubitemid 30253349)
25. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, et al,. (2007). Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27: 1500-1510. (Pubitemid 46986103)
26. Freeman-Anderson NE, Pickle TG, Netherland CD, Bales A, Buckley NE, Thewke DP, (2008). Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterol-induced apoptosis. J Lipid Res 49: 2338-2346.
27. Galiegue S, Mary S, Marchand J, Dussossoy D, Carriere D, Carayon P, et al,. (1995). Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232: 54-61.
28. Gerthoffer WT, (2007). Mechanisms of vascular smooth muscle cell migration. Circ Res 100: 607-621. (Pubitemid 46594875)
29. Ghosh S, Preet A, Groopman JE, Ganju RK, (2006). Cannabinoid receptor CB(2) modulates the CXCL12/CXCR4-mediated chemotaxis of T lymphocytes. Mol Immunol 43: 2169-2179. (Pubitemid 43831198)
30. Grimsey NL, Goodfellow CE, Dragunow M, Glass M, (2011). Cannabinoid receptor 2 undergoes Rab5-mediated internalization and recycles via a Rab11-dependent pathway. Biochim Biophys Acta 1813: 1554-1560.
31. Gruntzig AR, Senning A, Siegenthaler WE, (1979). Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med 301: 61-68. (Pubitemid 9229695)
32. Hajrasouliha AR, Tavakoli S, Ghasemi M, Jabehdar-Maralani P, Sadeghipour H, Ebrahimi F, et al,. (2008). Endogenous cannabinoids contribute to remote ischemic preconditioning via cannabinoid CB2 receptors in the rat heart. Eur J Pharmacol 579: 246-252.
33. Horvath B, Magid L, Mukhopadhyay P, Batkai S, Rajesh M, Park O, et al,. (2012). A new cannabinoid 2 receptor agonist HU-910 attenuates oxidative stress, inflammation, and cell death associated with hepatic ischemia/reperfusion injury. Br J Pharmacol 165: 2462-2478.
34. Howlett AC, (2005). Cannabinoid receptor signaling. Handb Exp Pharmacol 168: 53-79.
35. Hoyer FF, Steinmetz M, Zimmer S, Becker A, Lutjohann D, Buchalla R, et al,. (2011). Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J Mol Cell Cardiol 51: 1007-1014.
36. Jessup M, Brozena S, (2003). Heart failure. N Engl J Med 348: 2007-2018.
37. Jiang LS, Pu J, Han ZH, Hu LH, He B, (2009). Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages. Cardiovasc Res 81: 805-813.
38. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al,. (2006). Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 48: 193-202. (Pubitemid 43929240)
39. Joyeux M, Arnaud C, Godin-Ribuot D, Demenge P, Lamontagne D, Ribuot C, (2002). Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc Res 55: 619-625. (Pubitemid 34874956)
40. Kishimoto S, Gokoh M, Oka S, Muramatsu M, Kajiwara T, Waku K, et al,. (2003). 2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J Biol Chem 278: 24469-24475. (Pubitemid 37548598)
41. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, et al,. (2003). The cannabinoid system and immune modulation. J Leukoc Biol 74: 486-496. (Pubitemid 38040375)
42. Kobayashi Y, Arai S, Waku K, Sugiura T, (2001). Activation by 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, of p42/44 mitogen-activated protein kinase in HL-60 cells. J Biochem 129: 665-669. (Pubitemid 32499776)
43. Krylatov AV, Ugdyzhekova DS, Bernatskaya NA, Maslov LN, Mekhoulam R, Pertwee RG, et al,. (2001). Activation of type II cannabinoid receptors improves myocardial tolerance to arrhythmogenic effects of coronary occlusion and reperfusion. Bull Exp Biol Med 131: 523-525. (Pubitemid 34051335)
44. Lagneux C, Lamontagne D, (2001). Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br J Pharmacol 132: 793-796. (Pubitemid 32193634)
45. Lepicier P, Bouchard JF, Lagneux C, Lamontagne D, (2003). Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol 139: 805-815. (Pubitemid 36819608)
46. Lepicier P, Lagneux C, Sirois MG, Lamontagne D, (2007). Endothelial CB1-receptors limit infarct size through NO formation in rat isolated hearts. Life Sci 81: 1373-1380. (Pubitemid 47599529)
47. Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, et al,. (1996). Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 7: 330-335. (Pubitemid 26372454)
48. Libby P, Ridker PM, Hansson GK, (2011). Progress and challenges in translating the biology of atherosclerosis. Nature 473: 317-325.
49. Liu J, Thewke DP, Su YR, Linton MF, Fazio S, Sinensky MS, (2005). Reduced macrophage apoptosis is associated with accelerated atherosclerosis in low-density lipoprotein receptor-null mice. Arterioscler Thromb Vasc Biol 25: 174-179. (Pubitemid 40054272)
50. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, et al,. (2007). Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115: 1051-1058. (Pubitemid 46328299)
51. Lusis AJ, (2000). Atherosclerosis. Nature 407: 233-241.
52. Maier JA, Barenghi L, Bradamante S, Pagani F, (1996). Induction of human endothelial cell growth by mildly oxidized low density lipoprotein. Atherosclerosis 123: 115-121. (Pubitemid 26176577)
53. Marazzi J, Kleyer J, Paredes JM, Gertsch J, (2011). Endocannabinoid content in fetal bovine sera-unexpected effects on mononuclear cells and osteoclastogenesis. J Immunol Methods 373: 219-228.
54. Miller AM, Stella N, (2008). CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 153: 299-308.
55. Milman G, Maor Y, Abu-Lafi S, Horowitz M, Gallily R, Batkai S, et al,. (2006). N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A 103: 2428-2433. (Pubitemid 43271686)
56. Molica F, Matter CM, Burger F, Pelli G, Lenglet S, Zimmer A, et al,. (2012). The cannabinoid receptor CB2 protects against balloon-induced neointima formation. Am J Physiol Heart Circ Physiol 302: 1064-1074.
57. Montecucco F, Burger F, Mach F, Steffens S, (2008). CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol 294: H1145-H1155. (Pubitemid 351468709)
58. Montecucco F, Lenglet S, Braunersreuther V, Burger F, Pelli G, Bertolotto M, et al,. (2009). CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol 46: 612-620.
59. Montecucco F, Di Marzo V, da Silva RF, Vuilleumier N, Capettini L, Lenglet S, et al,. (2011). The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur Heart J 33: 846-856.
60. Mukhopadhyay P, Rajesh M, Batkai S, Patel V, Kashiwaya Y, Liaudet L, et al,. (2010a). CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res 85: 773-784.
61. Mukhopadhyay P, Rajesh M, Pan H, Patel V, Mukhopadhyay B, Batkai S, et al,. (2010b). Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med 48: 457-467.
62. Munro S, Thomas KL, Abu-Shaar M, (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65. (Pubitemid 23305569)
63. Murikinati S, Juttler E, Keinert T, Ridder DA, Muhammad S, Waibler Z, et al,. (2010). Activation of cannabinoid 2 receptors protects against cerebral ischemia by inhibiting neutrophil recruitment. FASEB J 24: 788-798.
64. Muslin AJ, (2008). MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond) 115: 203-218.
65. Netherland CD, Pickle TG, Bales A, Thewke DP, (2010). Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. Atherosclerosis 213: 102-108.
66. Ni X, Geller EB, Eppihimer MJ, Eisenstein TK, Adler MW, Tuma RF, (2004). Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 10: 158-164. (Pubitemid 38499908)
67. Pacher P, (2009). Cannabinoid CB1 receptor antagonists for atherosclerosis and cardiometabolic disorders: new hopes, old concerns? Arterioscler Thromb Vasc Biol 29: 7-9.
68. Pacher P, Hasko G, (2008). Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Br J Pharmacol 153: 252-262.
69. Pacher P, Mechoulam R, (2011). Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 50: 193-211.
70. Pertwee RG, (2005). Pharmacological actions of cannabinoids. Handb Exp Pharmacol 168: 1-51.
71. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Huffman JW, et al,. (2007a). CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 293: H2210-H2218. (Pubitemid 47605864)
72. Rajesh M, Pan H, Mukhopadhyay P, Batkai S, Osei-Hyiaman D, Hasko G, et al,. (2007b). Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol 82: 1382-1389. (Pubitemid 350276948)
73. Rajesh M, Mukhopadhyay P, Hasko G, Huffman JW, Mackie K, Pacher P, (2008). CB(2) cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol 153: 347-357.
74. Ramirez SH, Hasko J, Skuba A, Fan S, Dykstra H, McCormick R, et al,. (2012). Activation of cannabinoid receptor 2 attenuates leukocyte-endothelial cell interactions and blood-brain barrier dysfunction under inflammatory conditions. J Neurosci 32: 4004-4016.
75. Rao GK, Zhang W, Kaminski NE, (2004). Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells. J Leukoc Biol 75: 884-892. (Pubitemid 38580069)
76. Reinhard W, Stark K, Neureuther K, Sedlacek K, Fischer M, Baessler A, et al,. (2008). Common polymorphisms in the cannabinoid CB2 receptor gene (CNR2) are not associated with myocardial infarction and cardiovascular risk factors. Int J Mol Med 22: 165-174.
77. Ritter SL, Hall RA, (2009). Fine-tuning of GPCR activity by receptor-interacting proteins. Nat Rev Mol Cell Biol 10: 819-830.
78. Schuehly W, Paredes JM, Kleyer J, Huefner A, Anavi-Goffer S, Raduner S, et al,. (2011). Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists. Chem Biol 18: 1053-1064.
79. Shmist YA, Goncharov I, Eichler M, Shneyvays V, Isaac A, Vogel Z, et al,. (2006). Delta-9-tetrahydrocannabinol protects cardiac cells from hypoxia via CB2 receptor activation and nitric oxide production. Mol Cell Biochem 283: 75-83.
80. Shoemaker JL, Joseph BK, Ruckle MB, Mayeux PR, Prather PL, (2005). The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors. J Pharmacol Exp Ther 314: 868-875. (Pubitemid 41043873)
81. Smith TH, Sim-Selley LJ, Selley DE, (2010). Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol 160: 454-466.
82. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, et al,. (2005). Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434: 782-786. (Pubitemid 44739523)
83. Sun Y, (2009). Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res 81: 482-490.
84. Underdown NJ, Hiley CR, Ford WR, (2005). Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism. Br J Pharmacol 146: 809-816. (Pubitemid 41622247)
85. Vora DK, Fang ZT, Liva SM, Tyner TR, Parhami F, Watson AD, et al,. (1997). Induction of P-selectin by oxidized lipoproteins. Separate effects on synthesis and surface expression. Circ Res 80: 810-818. (Pubitemid 27230055)
86. Wagner JA, Abesser M, Harvey-White J, Ertl G, (2006). 2-Arachidonylglycerol acting on CB1 cannabinoid receptors mediates delayed cardioprotection induced by nitric oxide in rat isolated hearts. J Cardiovasc Pharmacol 47: 650-655. (Pubitemid 44309657)
87. Wang GP, Deng ZD, Ni J, Qu ZL, (1997). Oxidized low density lipoprotein and very low density lipoprotein enhance expression of monocyte chemoattractant protein-1 in rabbit peritoneal exudate macrophages. Atherosclerosis 133: 31-36. (Pubitemid 27322114)
88. Weber C, Schober A, Zernecke A, (2004). Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease. Arterioscler Thromb Vasc Biol 24: 1997-2008. (Pubitemid 39482421)
89. Weis F, Beiras-Fernandez A, Sodian R, Kaczmarek I, Reichart B, Beiras A, et al,. (2010). Substantially altered expression pattern of cannabinoid receptor 2 and activated endocannabinoid system in patients with severe heart failure. J Mol Cell Cardiol 48: 1187-1193.
90. Wiley JL, Beletskaya ID, Ng EW, Dai Z, Crocker PJ, Mahadevan A, et al,. (2002). Resorcinol derivatives: a novel template for the development of cannabinoid CB(1)/CB(2) and CB(2)-selective agonists. J Pharmacol Exp Ther 301: 679-689. (Pubitemid 34429984)
91. Willecke F, Zeschky K, Ortiz Rodriguez A, Colberg C, Auwarter V, Kneisel S, et al,. (2011). Cannabinoid receptor 2 signaling does not modulate atherogenesis in mice. PLoS ONE 6: e19405.
92. Zarruk JG, Fernandez-Lopez D, Garcia-Yebenes I, Garcia-Gutierrez MS, Vivancos J, Nombela F, et al,. (2012). Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection. Stroke 43: 211-219.
93. Zhang M, Martin BR, Adler MW, Razdan RK, Jallo JI, Tuma RF, (2007). Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab 27: 1387-1396. (Pubitemid 46985356)
94. Zhang M, Martin BR, Adler MW, Razdan RK, Ganea D, Tuma RF, (2008). Modulation of the balance between cannabinoid CB(1) and CB(2) receptor activation during cerebral ischemic/reperfusion injury. Neuroscience 152: 753-760.
95. Zhao Y, Liu Y, Zhang W, Xue J, Wu YZ, Xu W, et al,. (2010a). WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice. Eur J Pharmacol 649: 285-292.
96. Zhao Y, Yuan Z, Liu Y, Xue J, Tian Y, Liu W, et al,. (2010b). Activation of cannabinoid CB2 receptor ameliorates atherosclerosis associated with suppression of adhesion molecules. J Cardiovasc Pharmacol 55: 292-298.
97. Zoratti C, Kipmen-Korgun D, Osibow K, Malli R, Graier WF, (2003). Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. Br J Pharmacol 140: 1351-1362. (Pubitemid 38067842)